Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Single-arm study conducted in participants for the treatment of urinary urge incontinence in patients who have failed, could not tolerate, or were not a candidate for more conservative treatments. The objective of the study is to assess the effectiveness of 30-minutes daily therapeutic stimulation with the Neuspera System.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Healthy Volunteers: f
View:

• Is male or female 22 years of age or older.

• Has a diagnosis of UUI for greater than or equal to 6 months prior to the screening baseline visit date.

• Has failed, could not tolerate (stopped taking medication due to lack of efficacy or intolerable side effects), or not a good candidate for (as determined by treating physician) at least one (1) antimuscarinic or β3 adrenoceptor agonist medication.

• Is willing and able to washout (at least five half-lives) from OAB medications for a period determined appropriate based on type of OAB medication prior to the baseline bladder diary and remain off OAB medications through the study duration OR must be willing to maintain medication through the study duration.

• Has a diagnosis of UUI with at least 4 UUI episodes on a 72-hour diary.

• Has a positive stimulation trial with a 50% reduction in UUI episodes.

Locations
United States
South Carolina
Southern Urogynecology, LLC
RECRUITING
West Columbia
Contact Information
Primary
Mark Vollmer
mark.vollmer@neuspera.com
408-433-3839
Backup
Shital Patel
shital.patel@neuspera.com
323-528-1320
Time Frame
Start Date: 2025-11-19
Estimated Completion Date: 2026-11
Participants
Target number of participants: 20
Treatments
Other: Neuspera Implantable Sacral Nerve Stimulation System
Implantation of the stimulator to assess effectiveness with shorter duration of stimulation
Sponsors
Leads: Neuspera Medical, Inc.

This content was sourced from clinicaltrials.gov